To evaluate the role of P2X1 in AML development, we first measured P2x1 mRNA levels in immunophenotypic Lin–Sca-1+c-Kit+CD34-Flt3- LT-HSCs and Mac-1+c-Kit+ LICs or Lin–Sca-1+c-Kit+CD34+CD16/CD32+ L-GMP cells (a population more highly enriched in LICs, Fig. 1A). This evidence concerns the gene FLT3 and acute myeloid leukemia.